News DexCom, Inc.

Stocks

DXCM

US2521311074

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 17:45:06 10/11/2026 GMT			5-day change	1st Jan Change
79.97 ^USD	-1.36%		-4.04%	+19.96%

10-30	DexCom Q3 Results, Higher Revenue Guidance Point to Stronger 2027, RBC Says	MT
10-30	UBS Adjusts DexCom Price Target to $107 From $102, Maintains Buy Rating	MT

All News

Mentions Relevance

aa6e5a98e06cf648119a0e6ec1b5eb.XVZdyLNZOOGfbETlLE_SxSvjZ9AsMcVI7OMkpXqysxc.Hzs8pOYLYqTMBgLWfSXijx66AeNUYpYwvpVKzSzthWYWJBOFhBxJl-sqfA

02:11pm	Dexcom Announces Upcoming Conference Presentation	BU
11-02	Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign	BU
10-30	DexCom Q3 Results, Higher Revenue Guidance Point to Stronger 2027, RBC Says	MT
10-30	UBS Adjusts DexCom Price Target to $107 From $102, Maintains Buy Rating	MT
10-30	Raymond James Adjusts Price Target on DexCom to $97 From $94	MT
10-30	Barclays Adjusts Price Target on DexCom to $120 From $115	MT
10-29	DexCom, Inc., Q3 2026 Earnings Call, Oct 29, 2026
10-29	DexCom Q3 Adjusted Earnings, Revenue Rise; Lifts 2026 Revenue Guidance	MT
10-29	(DXCM) DexCom Expects Full Year 2026 Revenue Range $5.20B - $5.25B, vs. FactSet Est of $5.23B	MT
10-29	Earnings Flash (DXCM) DexCom, Inc. Reports Q3 Revenue $1.34B, vs. FactSet Est of $1.33B	MT
10-29	Earnings Flash (DXCM) DexCom, Inc. Posts Q3 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.67	MT
10-29	Dexcom Reports Third Quarter 2026 Financial Results	BU
10-29	DexCom, Inc. announces an Equity Buyback for $1,000 million worth of its shares.	CI
10-29	DexCom, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
10-29	Dexcom, Inc. Raises Earnings Guidance for the Fiscal Year 2026	CI
10-28	DexCom, Inc. authorizes a Buyback Plan.	CI
10-28	DexCom, Inc. Launches Dexcom G7 15 Day Continuous Glucose Monitoring System In Canada	CI
10-28	Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November	BU
10-26	Leerink Partners Adjusts Price Target on DexCom to $87 From $94	MT
10-14	Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin	BU
10-14	DexCom, Inc. Announces Publication Of CONNECT Study Results For Dexcom G7 In The New England Journal Of Medicine	CI
10-13	Mizuho Adjusts Price Target on DexCom to $100 From $95	MT
10-12	BTIG Adjusts Price Target on DexCom to $96 From $90	MT
10-07	Evercore ISI Adjusts Price Target on DexCom to $110 From $90	MT
10-07	Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time	BU